Predicting Immunogenicity of Protein Therapeutics

Because recombinant protein therapeutics are genetically engineered, they have the potential to induce an immunogenic response in a patient.  Immunogenicity risk, as defined by the formation of anti-drug antibodies (ADA),…

Comments Off on Predicting Immunogenicity of Protein Therapeutics

Taking Charge of Charge Variants

A principal reason for why the manufacture of biologics is difficult is the structural complexity of the recombinant glycoproteins that are being produced.  As biologics production moves from research and…

Comments Off on Taking Charge of Charge Variants

CAR-T cells: Beyond CD19

CAR-T cells are a new and exciting drug class in which treatment involves the use of transformed immune cells for cancer therapy. A patient’s T- cells are removed, transduced and expanded…

Comments Off on CAR-T cells: Beyond CD19

Cutting mAbs with precision: GingisKHAN™

As multivalent antibodies find their way to the therapeutics market, the ability to evaluate affinity and avidity becomes a key step to their success.  Separating individual binding units by cutting…

Comments Off on Cutting mAbs with precision: GingisKHAN™
  • 1
  • 2
Close Menu